达格列净对急性心肌梗死合并糖尿病患者经皮冠状动脉介入治疗后糖代谢、心功能的影响分析  

Analysis of the Effects of Dagliflozin on Glucose Metabolism and Cardiac Function after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction and Diabetes Mellitus

作　　者：唐玲玲[1] TANG Lingling(Department of Cardiology,Dalian University Zhongshan Hospital,Dalian,Liaoning 116001,China)

机构地区：[1]大连大学附属中山医院循环内科,辽宁大连116001

出　　处：《中国医药指南》2025年第12期99-101,共3页Guide of China Medicine

摘　　要：目的 研究达格列净应用于采用经皮冠状动脉介入术(PCI)治疗的急性心肌梗死(AMI)合并2型糖尿病患者术后降糖方案中对糖代谢、心功能改善的影响。方法 选取大连大学附属中山医院在2023年8月至2024年6月诊治的AMI合并2型糖尿病的患者114例为研究对象,均在本院导管室接受PCI治疗,根据术后降糖治疗方案分组,对照组(n=62)采用胰岛素和原先的口服降糖药治疗,观察组(n=52)在对照组的基础上给予达格列净治疗。比较两组治疗效果。结果 观察组患者治疗6个月后的空腹血糖、糖化血红蛋白水平均低于对照组(P<0.05);在心功能指标的对比上,观察组的LVEDD和ESVI低于对照组,且LVEF和LVMI均高于对照组(P<0.05);治疗6个月后的心肌TIMI血流帧数(CTFC)和心肌灌注分级(TMPG)比较,观察组均低于对照组(P<0.05);跟踪随访6~12个月,观察组的MACE发生率及心力衰竭再住院率均低于对照组(P<0.05);两组药物不良反应发生率比较差异无统计学意义(P> 0.05)。结论 达格列净应用于AMI合并糖尿病患者PCI介入术后的降糖方案中效果肯定,能促进血糖控制,并改善患者的心功能,减少心血管不良事件发生,安全性高。Objective To study the effect of daggligin on glucose metabolism and cardiac function in patients with acute myocardial infarction(AMI)and type 2 diabetes after percutaneous coronary intervention(PCI).Methods All 114 patients with AMI with type 2 diabetes from August 2023 to June 2024,who received PCI in the catheterization room of our hospital,the control group(n=62)was treated with insulin and original oral hypoglycemic drugs,and the observation group(n=52)was administered dagliflozin on the basis of the control group.Comparison of treatment outcomes between the two groups.Results The fasting blood glucose and hemoglobin levels of patients in the observation group were lower than those in the control group(P<0.05).In terms of comparison of cardiac function indicators,the LVEDD and ESVI of the observation group were lower than those of the control group,and LVEF and LVMI were both higher than those of the control group(P<0.05).Comparison of myocardial TIMI flow frames(CTFC)and myocardial perfusion grade(TMPG)after 6 months of treatment,the observation group was lower than that of the control group(P<0.05).Follow-up visits ranged from 6 to 12 months,the incidence of MACE and heart failure in the observation group were lower than that in the control group(P<0.05).The difference in the incidence of adverse drug reactions was not significant(P>0.05).Conclusions The application of daggligin in the hypoglycemic program after PCI intervention in patients with AMI and diabetes has a positive effect,can promote blood sugar control,improve patients’cardiac function,reduce cardiovascular adverse events,and has high safety.

关 键 词：急性心肌梗死 2型糖尿病 达格列净 经皮冠状动脉介入术 心功能 糖代谢 

分 类 号：R542.22[医药卫生—心血管疾病] R587.1[医药卫生—内科学]